Crossmark

Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer

Published Online: 2024-12-03

Published Print: 2025-02

Authors

Cascone, Tina

William, William N. Jr.
License Information

Text and Data Mining valid from 2024-12-03

Version of Record valid from 2024-12-03
More Information

Article History

First Online: 3 December 2024

Competing interests

: T.C. has acted as a consultant and/or advisor and/or speaker for, and/or has received travel support from ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, Genentech, IDEOlogy Health, Medical Educator Consortium, Medscape, Merck, OncLive, oNKo-innate, PEAK Medicals, PeerView, Pfizer, Physicians’ Education Resource, RAPT Therapeutics, Regeneron, and Targeted Oncology. W.N.W.Jr. has acted as a consultant and/or advisor and/or speaker for, and/or has received travel support from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly, Genentech/Roche, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi-Aventis, Takeda and United Medical.

Document is current